---
layout: default
title: Carisoprodol
description: "Carisoprodol çš„è€è—¥æ–°ç”¨æ½›åŠ›åˆ†æã€‚æ¨¡å‹é æ¸¬ç­‰ç´š L5ï¼ŒåŒ…å« 1 å€‹é æ¸¬é©æ‡‰ç—‡ã€‚æŸ¥çœ‹ AI é æ¸¬èˆ‡è‡¨åºŠè­‰æ“šå®Œæ•´å ±å‘Šã€‚"
parent: åƒ…æ¨¡å‹é æ¸¬ (L5)
nav_order: 41
evidence_level: L5
indication_count: 1
---

# Carisoprodol

<p style="font-size: 1.25rem; color: #666; margin-bottom: 1.5rem;">
è­‰æ“šç­‰ç´š: <strong>L5</strong> | é æ¸¬é©æ‡‰ç—‡: <strong>1</strong> å€‹
</p>

---

<div id="pharmacist">

## è—¥å¸«è©•ä¼°å ±å‘Š

</div>

# Carisoprodolï¼šå¾è‚Œè‚‰é¬†å¼›åˆ°å¤±çœ çš„æ½›åœ¨æ‡‰ç”¨

## ä¸€å¥è©±ç¸½çµ

<p class="key-answer" data-question="Carisoprodol å¯ä»¥ç”¨æ–¼æ²»ç™‚ä»€éº¼æ–°é©æ‡‰ç—‡ï¼Ÿ">
Carisoprodol æ˜¯ä¸­æ¨æ€§è‚Œè‚‰é¬†å¼›åŠ‘ï¼Œä¸»è¦ç”¨æ–¼ç·©è§£è‚Œè‚‰ç—™æ”£å’Œç–¼ç—›ã€‚
TxGNN æ¨¡å‹é æ¸¬å®ƒå¯èƒ½å°**å¤±çœ  (insomnia)** æœ‰æ•ˆï¼Œ
ç›®å‰æœ‰ **1 ç¯‡æ–‡ç»**é–“æ¥æ”¯æŒå…¶é®éœä½œç”¨èˆ‡ç¡çœ çš„é—œè¯ã€‚
</p>


## å¿«é€Ÿç¸½è¦½

| é …ç›® | å…§å®¹ |
|------|------|
| åŸé©æ‡‰ç—‡ | ç„¦æ…®ç·Šå¼µç—‡ã€è‚Œç‚ã€æ¤é–“ç¥ç¶“ç—›ã€åéª¨ç¥ç¶“ç—›ã€é ¸ç—›ã€é¢¨æ¿•æ€§é—œç¯€ç‚ã€éª¨é—œç¯€ç‚ã€è‚Œè‚‰åƒµç¡¬ã€è‚Œè‚‰ç—› |
| é æ¸¬æ–°é©æ‡‰ç—‡ | insomnia (disease) |
| TxGNN é æ¸¬åˆ†æ•¸ | 99.02% |
| è­‰æ“šç­‰ç´š | L5 |
| å°ç£ä¸Šå¸‚ | å·²ä¸Šå¸‚ |
| è¨±å¯è­‰æ•¸ | 38 å¼µï¼ˆå«å·²è¨»éŠ·ï¼‰ |
| å»ºè­°æ±ºç­– | Hold |

## ç‚ºä»€éº¼é€™å€‹é æ¸¬åˆç†ï¼Ÿ

Carisoprodol æ˜¯ä¸€ç¨®ä¸­æ¨ä½œç”¨çš„è‚Œè‚‰é¬†å¼›åŠ‘ï¼Œå…¶ä½œç”¨æ©Ÿè½‰èˆ‡é æ¸¬é©æ‡‰ç—‡çš„é—œè¯ï¼š

1. **ä¸­æ¨ç¥ç¶“ç³»çµ±æŠ‘åˆ¶ä½œç”¨**ï¼šCarisoprodol åœ¨é«”å…§éƒ¨åˆ†ä»£è¬ç‚º meprobamateï¼ˆä¸€ç¨®å…·æœ‰é®éœä½œç”¨çš„ä»£è¬ç‰©ï¼‰ï¼Œå¯èƒ½å½±éŸ¿ç¡çœ 
2. **GABA å—é«”èª¿ç¯€**ï¼šå…¶ä»£è¬ç‰© meprobamate å…·æœ‰é¡ä¼¼å·´æ¯”å¦¥é¡è—¥ç‰©çš„ GABA-A å—é«”èª¿ç¯€ä½œç”¨
3. **è‚Œè‚‰ç—™æ”£èˆ‡å¤±çœ çš„é—œè¯**ï¼šæ–‡ç»æåˆ°å¤œé–“è…¿éƒ¨ç—™æ”£å¯å°è‡´åš´é‡å¤±çœ ï¼Œè€Œ carisoprodol ç”¨æ–¼ç·©è§£è‚Œè‚‰ç—™æ”£

ç„¶è€Œï¼Œé€™ä¸€é æ¸¬çš„è‡¨åºŠç›¸é—œæ€§æœ‰é™ï¼Œä¸»è¦å› ç‚ºï¼š
- ç¼ºä¹ç›´æ¥é‡å°å¤±çœ é©æ‡‰ç—‡çš„è‡¨åºŠè©¦é©—
- å­˜åœ¨æ¿«ç”¨å’Œä¾è³´æ€§é¢¨éšª
- æœ‰æ›´å®‰å…¨æœ‰æ•ˆçš„å¤±çœ æ²»ç™‚é¸æ“‡

## è‡¨åºŠè©¦é©—è­‰æ“š

ç›®å‰ç„¡ç›´æ¥é‡å° carisoprodol æ²»ç™‚å¤±çœ çš„è‡¨åºŠè©¦é©—ã€‚

## æ–‡ç»è­‰æ“š

| PMID | å¹´ä»½ | é¡å‹ | æœŸåˆŠ | ä¸»è¦ç™¼ç¾ |
|------|-----|------|------|---------|
| [22963024](https://pubmed.ncbi.nlm.nih.gov/22963024/) | 2012 | Review | American Family Physician | æ¢è¨å¤œé–“è…¿éƒ¨ç—™æ”£å°è‡´åš´é‡å¤±çœ çš„å•é¡Œï¼ŒæåŠ carisoprodol ç­‰è‚Œè‚‰é¬†å¼›åŠ‘ç”¨æ–¼ç·©è§£ç—‡ç‹€ |

## å°ç£ä¸Šå¸‚è³‡è¨Š

| è¨±å¯è­‰è™Ÿ | å“å | åŠ‘å‹ | æ ¸å‡†é©æ‡‰ç—‡ |
|---------|------|------|-----------|
| è¡›éƒ¨è—¥è£½å­—ç¬¬058303è™Ÿ | å¡é¬†éŒ 250æ¯«å…‹ | éŒ åŠ‘ | ç„¦æ…®ç·Šå¼µç—‡ã€è‚Œç‚ã€æ¤é–“ç¥ç¶“ç—›ã€åéª¨ç¥ç¶“ç—›ã€é ¸ç—›ã€é¢¨æ¿•æ€§é—œç¯€ç‚ã€éª¨é—œç¯€ç‚ã€è‚Œè‚‰åƒµç¡¬ã€è‚Œè‚‰ç—› |
| è¡›éƒ¨è—¥è£½å­—ç¬¬058030è™Ÿ | "å…ƒå®™"è‚Œèˆ’é”éŒ  | éŒ åŠ‘ | ç„¦æ…®ç·Šå¼µç—‡ã€ç¶“å¸¸ç·Šå¼µã€è‚Œç‚ã€æ¤é–“ç¥ç¶“ç—›ã€åéª¨ç¥ç¶“ç—›ã€é ¸ç—›ã€é¢¨æ¿•æ€§é—œç¯€ç‚ã€éª¨é—œç¯€ç‚ã€è‚Œè‚‰åƒµç¡¬ã€è‚Œè‚‰ç—› |
| è¡›éƒ¨è—¥è£½å­—ç¬¬058551è™Ÿ | å¯èˆ’åˆ©ç­‹éŒ 350æ¯«å…‹ | éŒ åŠ‘ | ç„¦æ…®ç·Šå¼µç—‡ã€ç¶“å¸¸ç·Šå¼µã€è‚Œç‚ã€æ¤é–“ç¥ç¶“ç—›ã€åéª¨ç¥ç¶“ç—›ã€é ¸ç—›ã€é¢¨æ¿•æ€§é—œç¯€ç‚ã€éª¨é—œç¯€ç‚ã€è‚Œè‚‰åƒµç¡¬ã€è‚Œè‚‰ç—› |
| è¡›ç½²è—¥è£½å­—ç¬¬055961è™Ÿ | å¡åŠ›èˆ’éŒ 250æ¯«å…‹ | éŒ åŠ‘ | ç„¦æ…®ç·Šå¼µç—‡ã€è‚Œç‚ã€æ¤é–“ç¥ç¶“ç—›ã€åéª¨ç¥ç¶“ç—›ã€é ¸ç—›ã€é¢¨æ¿•æ€§é—œç¯€ç‚ã€éª¨é—œç¯€ç‚ã€è‚Œè‚‰åƒµç¡¬ã€è‚Œè‚‰ç—› |
| è¡›éƒ¨è—¥è¼¸å­—ç¬¬028545è™Ÿ | å¡åˆ©ç´¢æ™®è‹¥å¤š | ï¼ˆç²‰ï¼‰ | éª¨éª¼è‚Œå¼›ç·©åŠ‘ |

## å®‰å…¨æ€§è€ƒé‡

**é‡è¦è­¦èª**ï¼š
- Carisoprodol å…·æœ‰æ¿«ç”¨å’Œä¾è³´æ€§é¢¨éšªï¼Œåœ¨éƒ¨åˆ†åœ‹å®¶å·²è¢«åˆ—ç‚ºç®¡åˆ¶è—¥å“
- ä»£è¬ç‰© meprobamate å¯èƒ½ç´¯ç©ä¸¦å°è‡´éåº¦é®éœ
- ä¸å»ºè­°é•·æœŸä½¿ç”¨ï¼Œé€šå¸¸é™æ–¼ 2-3 é€±çŸ­æœŸæ²»ç™‚

**è—¥ç‰©äº¤äº’ä½œç”¨**ï¼š
- èˆ‡ Morphineï¼ˆMajorï¼‰ï¼šå¯èƒ½å¢å¼·ä¸­æ¨ç¥ç¶“ç³»çµ±æŠ‘åˆ¶ä½œç”¨ï¼Œå°è‡´å‘¼å¸æŠ‘åˆ¶
- èˆ‡ Morphine (liposomal)ï¼ˆMajorï¼‰ï¼šåŒä¸Š
- èˆ‡ Dronabinolï¼ˆModerateï¼‰ï¼šå¢å¼·é®éœä½œç”¨
- èˆ‡ Nabiloneï¼ˆModerateï¼‰ï¼šå¢å¼·é®éœä½œç”¨
- èˆ‡ Opiumï¼ˆModerateï¼‰ï¼šå¯èƒ½å¢å¼·ä¸­æ¨ç¥ç¶“ç³»çµ±æŠ‘åˆ¶
- èˆ‡ Metoclopramideï¼ˆModerateï¼‰ï¼šå¯èƒ½å¢å¼·é®éœä½œç”¨

**ç‰¹æ®Šæ—ç¾¤æ³¨æ„äº‹é …**ï¼š
- è€å¹´æ‚£è€…ï¼šå› ä»£è¬ç‰©ç´¯ç©é¢¨éšªï¼Œéœ€è¬¹æ…ä½¿ç”¨
- è‚åŠŸèƒ½ä¸å…¨ï¼šå¯èƒ½å½±éŸ¿è—¥ç‰©ä»£è¬
- å…·æœ‰è—¥ç‰©æ¿«ç”¨å²è€…ï¼šä¸å»ºè­°ä½¿ç”¨

### è—¥ç‰©-é£Ÿç‰©äº¤äº’ä½œç”¨ (DFI)

<div class="dfi-source">è³‡æ–™ä¾†æºï¼š<a href="https://ddinter2.scbdd.com/" target="_blank">DDInter 2.0</a></div>

**é…’ç²¾ (alcohol)** ğŸŸ¡ Moderate
- å½±éŸ¿ï¼šAlcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and...
- å»ºè­°ï¼šPatients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities r...

### è—¥ç‰©-è‰è—¥äº¤äº’ä½œç”¨ (DHI)

**å¡ç“¦** ğŸ”´ Major
- å½±éŸ¿ï¼šåš´é‡ä¸­æ¨ç¥ç¶“æŠ‘åˆ¶
- å»ºè­°ï¼šç¦æ­¢ä½µç”¨

**çºˆè‰** ğŸŸ¡ Moderate
- å½±éŸ¿ï¼šå¢å¼·é®éœä½œç”¨
- å»ºè­°ï¼šé¿å…ä½µç”¨



### è—¥ç‰©-ç–¾ç—…æ³¨æ„äº‹é … (DDSI)

<div class="ddsi-source">è³‡æ–™ä¾†æºï¼š<a href="https://ddinter2.scbdd.com/" target="_blank">DDInter 2.0</a></div>

**Substance-Related Disorders** ğŸŸ¡ Moderate
- Carisoprodol is partially metabolized to meprobamate, a pharmacologically active agent with known addictive potential.  According to the manufacturer, abrupt cessation of carisoprodol 100 mg/kg/day (approximately 5 times the recommended daily adult d...

**è‚è‡Ÿç–¾ç—… (Liver Diseases)** ğŸŸ¡ Moderate
- Carisoprodol is primarily converted in the liver to several metabolites, one of which (meprobamate) is pharmacologically active.  The metabolites and a small amount of the parent drug are excreted in the urine.  Patients with impaired renal and/or he...

**Porphyrias** ğŸŸ¢ Minor
- The use of carisoprodol is contraindicated in patients with acute intermittent porphyria.  Carisoprodol is partially metabolized to the pharmacologically active meprobamate, which has been reported to precipitate acute attacks of porphyria in suscept...

## çµè«–èˆ‡ä¸‹ä¸€æ­¥

**æ±ºç­–ï¼šHold**

**ç†ç”±ï¼š**
é›–ç„¶ carisoprodol çš„é®éœä½œç”¨å¯èƒ½å°ç¡çœ æœ‰ä¸€å®šå½±éŸ¿ï¼Œä½†ç¼ºä¹ç›´æ¥çš„è‡¨åºŠè©¦é©—è­‰æ“šæ”¯æŒå…¶ç”¨æ–¼å¤±çœ æ²»ç™‚ã€‚æ­¤å¤–ï¼Œè©²è—¥ç‰©å­˜åœ¨æ¿«ç”¨é¢¨éšªï¼Œä¸”æœ‰æ›´å®‰å…¨æœ‰æ•ˆçš„å¤±çœ æ²»ç™‚é¸æ“‡ã€‚

**è‹¥è¦æ¨é€²éœ€è¦ï¼š**
- é‡å°å¤±çœ é©æ‡‰ç—‡çš„å‰ç»æ€§è‡¨åºŠè©¦é©—
- å®‰å…¨æ€§è©•ä¼°ï¼Œç‰¹åˆ¥æ˜¯æ¿«ç”¨å’Œä¾è³´æ€§é¢¨éšª
- èˆ‡ç¾æœ‰å¤±çœ æ²»ç™‚è—¥ç‰©çš„æ¯”è¼ƒç ”ç©¶
- è€ƒæ…®å…¶ä»–æ›´å®‰å…¨çš„æ²»ç™‚é¸é …


---

## ç›¸é—œè—¥ç‰©å ±å‘Š

- [Ouabain]({{ "/drugs/ouabain/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Bevacizumab]({{ "/drugs/bevacizumab/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Threonine]({{ "/drugs/threonine/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Alirocumab]({{ "/drugs/alirocumab/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Nitrofurantoin]({{ "/drugs/nitrofurantoin/" | relative_url }}) - è­‰æ“šç­‰ç´š L5

---

{% include ai-analysis.html %}

{% include social-share.html %}

## å¼•ç”¨æœ¬å ±å‘Š

å¦‚éœ€å¼•ç”¨æœ¬å ±å‘Šï¼Œè«‹ä½¿ç”¨ä»¥ä¸‹æ ¼å¼ï¼š

**APA æ ¼å¼ï¼š**
```
TwTxGNN. (2026). Carisoprodolè€è—¥æ–°ç”¨é©—è­‰å ±å‘Š. https://twtxgnn.yao.care/drugs/carisoprodol/
```

**BibTeX æ ¼å¼ï¼š**
```bibtex
@misc{twtxgnn_carisoprodol,
  title = {Carisoprodolè€è—¥æ–°ç”¨é©—è­‰å ±å‘Š},
  author = {TwTxGNN Team},
  year = {2026},
  url = {https://twtxgnn.yao.care/drugs/carisoprodol/}
}
```

---

<div class="disclaimer">
<strong>å…è²¬è²æ˜</strong><br>
æœ¬å ±å‘Šåƒ…ä¾›å­¸è¡“ç ”ç©¶åƒè€ƒï¼Œ<strong>ä¸æ§‹æˆé†«ç™‚å»ºè­°</strong>ã€‚è—¥ç‰©ä½¿ç”¨è«‹éµå¾ªé†«å¸«æŒ‡ç¤ºï¼Œåˆ‡å‹¿è‡ªè¡Œèª¿æ•´ç”¨è—¥ã€‚ä»»ä½•è€è—¥æ–°ç”¨æ±ºç­–éœ€ç¶“éå®Œæ•´çš„è‡¨åºŠé©—è­‰èˆ‡æ³•è¦å¯©æŸ¥ã€‚
<br><br>
<small>æœ€å¾Œå¯©æ ¸ï¼š2026-02-20 | å¯©æ ¸è€…ï¼šTwTxGNN Research Team</small>
</div>

{% include giscus.html %}
